In an attempt to bolster its oncology pipeline, Takeda has signed a license and collaboration agreement with Innovent Biologics worth up to US$11.4 B for global rights outside of Greater China to two next-generation late-stage cancer medicines: IBI363, a PD-1/IL-2alpha-bias bispecific antibody fusion protein and IBI343, a CLDN18.2 antibody-drug conjugate (ADC). Takeda also holds an exclusive option to license global rights to an early-stage bispecific ADC, IBI3001. The deal comes shortly after Takeda announced it was withdrawing from the cell therapy field and re-focusing on late-stage candidates in R&D.